



CNMV
Markets Directorate General
C/Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), 6th April 2017

Pursuant to article 228 of the consolidated text of the Spanish Securities Market Act, Pharma Mar, S.A. announces that it will host a Research and Development Event in New York on April 24th, 2017 (10:30 am –1:30 pm ET; 16:30-19:30 CEST). Members of PharmaMar’s senior management team and several experts will discuss scientific pipeline including; Phase 3 pivotal study with lurbinectedin (PM1183), current and prospective clinical trials, small-cell lung cancer and hereditary breast cancers, and an overview of Company strategy.

The presentation will be webcast simultaneously on the calendar section of the Company’s Events Calendar page of the website at www.pharmamar.com

A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the same section of the company's website at www.pharmamar.com.